|
Gene: DYNLL1 |
Gene summary for DYNLL1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | DYNLL1 | Gene ID | 8655 |
Gene name | dynein light chain LC8-type 1 | |
Gene Alias | DLC1 | |
Cytomap | 12q24.31 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P63167 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
8655 | DYNLL1 | GSM4909277 | Human | Breast | Precancer | 1.57e-04 | 5.35e-01 | 0.0177 |
8655 | DYNLL1 | GSM4909280 | Human | Breast | Precancer | 2.23e-02 | 1.96e-01 | 0.0305 |
8655 | DYNLL1 | GSM4909281 | Human | Breast | IDC | 6.83e-17 | 4.48e-01 | 0.21 |
8655 | DYNLL1 | GSM4909282 | Human | Breast | IDC | 6.13e-05 | 3.12e-01 | -0.0288 |
8655 | DYNLL1 | GSM4909285 | Human | Breast | IDC | 4.89e-22 | 5.19e-01 | 0.21 |
8655 | DYNLL1 | GSM4909286 | Human | Breast | IDC | 7.88e-10 | 1.09e-01 | 0.1081 |
8655 | DYNLL1 | GSM4909288 | Human | Breast | IDC | 2.50e-10 | 4.83e-01 | 0.0988 |
8655 | DYNLL1 | GSM4909290 | Human | Breast | IDC | 2.92e-17 | 5.00e-01 | 0.2096 |
8655 | DYNLL1 | GSM4909291 | Human | Breast | IDC | 1.61e-14 | 4.83e-01 | 0.1753 |
8655 | DYNLL1 | GSM4909293 | Human | Breast | IDC | 6.04e-13 | 4.23e-01 | 0.1581 |
8655 | DYNLL1 | GSM4909296 | Human | Breast | IDC | 2.79e-17 | 3.59e-01 | 0.1524 |
8655 | DYNLL1 | GSM4909297 | Human | Breast | IDC | 3.92e-28 | 3.06e-01 | 0.1517 |
8655 | DYNLL1 | GSM4909298 | Human | Breast | IDC | 3.10e-05 | 2.44e-01 | 0.1551 |
8655 | DYNLL1 | GSM4909299 | Human | Breast | IDC | 7.86e-04 | 2.90e-01 | 0.035 |
8655 | DYNLL1 | GSM4909301 | Human | Breast | IDC | 3.67e-16 | 4.32e-01 | 0.1577 |
8655 | DYNLL1 | GSM4909304 | Human | Breast | IDC | 1.04e-26 | 4.78e-01 | 0.1636 |
8655 | DYNLL1 | GSM4909306 | Human | Breast | IDC | 6.56e-20 | 4.47e-01 | 0.1564 |
8655 | DYNLL1 | GSM4909307 | Human | Breast | IDC | 1.73e-05 | 3.17e-01 | 0.1569 |
8655 | DYNLL1 | GSM4909308 | Human | Breast | IDC | 2.11e-09 | 3.50e-01 | 0.158 |
8655 | DYNLL1 | GSM4909309 | Human | Breast | IDC | 2.09e-19 | 4.44e-01 | 0.0483 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190495125 | Oral cavity | EOLP | positive regulation of establishment of protein localization | 73/2218 | 319/18723 | 1.80e-08 | 7.94e-07 | 73 |
GO:0009743110 | Oral cavity | EOLP | response to carbohydrate | 49/2218 | 253/18723 | 3.41e-04 | 3.15e-03 | 49 |
GO:002176224 | Oral cavity | EOLP | substantia nigra development | 14/2218 | 44/18723 | 3.72e-04 | 3.38e-03 | 14 |
GO:000167817 | Oral cavity | EOLP | cellular glucose homeostasis | 36/2218 | 172/18723 | 4.51e-04 | 3.98e-03 | 36 |
GO:0034284110 | Oral cavity | EOLP | response to monosaccharide | 44/2218 | 225/18723 | 5.38e-04 | 4.63e-03 | 44 |
GO:0009746110 | Oral cavity | EOLP | response to hexose | 43/2218 | 219/18723 | 5.67e-04 | 4.81e-03 | 43 |
GO:003577412 | Oral cavity | EOLP | positive regulation of insulin secretion involved in cellular response to glucose stimulus | 12/2218 | 36/18723 | 6.02e-04 | 5.04e-03 | 12 |
GO:004542816 | Oral cavity | EOLP | regulation of nitric oxide biosynthetic process | 17/2218 | 62/18723 | 6.56e-04 | 5.46e-03 | 17 |
GO:008016416 | Oral cavity | EOLP | regulation of nitric oxide metabolic process | 17/2218 | 64/18723 | 9.71e-04 | 7.35e-03 | 17 |
GO:007133317 | Oral cavity | EOLP | cellular response to glucose stimulus | 31/2218 | 151/18723 | 1.50e-03 | 1.01e-02 | 31 |
GO:00320247 | Oral cavity | EOLP | positive regulation of insulin secretion | 19/2218 | 78/18723 | 1.56e-03 | 1.05e-02 | 19 |
GO:007133117 | Oral cavity | EOLP | cellular response to hexose stimulus | 31/2218 | 153/18723 | 1.87e-03 | 1.21e-02 | 31 |
GO:000974918 | Oral cavity | EOLP | response to glucose | 40/2218 | 212/18723 | 1.89e-03 | 1.21e-02 | 40 |
GO:007132617 | Oral cavity | EOLP | cellular response to monosaccharide stimulus | 31/2218 | 154/18723 | 2.08e-03 | 1.32e-02 | 31 |
GO:005071415 | Oral cavity | EOLP | positive regulation of protein secretion | 28/2218 | 137/18723 | 2.65e-03 | 1.59e-02 | 28 |
GO:007132218 | Oral cavity | EOLP | cellular response to carbohydrate stimulus | 32/2218 | 163/18723 | 2.70e-03 | 1.62e-02 | 32 |
GO:000680916 | Oral cavity | EOLP | nitric oxide biosynthetic process | 18/2218 | 76/18723 | 2.85e-03 | 1.69e-02 | 18 |
GO:004259317 | Oral cavity | EOLP | glucose homeostasis | 46/2218 | 258/18723 | 2.96e-03 | 1.74e-02 | 46 |
GO:003350017 | Oral cavity | EOLP | carbohydrate homeostasis | 46/2218 | 259/18723 | 3.20e-03 | 1.86e-02 | 46 |
GO:003090123 | Oral cavity | EOLP | midbrain development | 20/2218 | 90/18723 | 3.81e-03 | 2.11e-02 | 20 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0513218 | Breast | Precancer | Salmonella infection | 49/684 | 249/8465 | 2.92e-09 | 6.15e-08 | 4.71e-08 | 49 |
hsa0513219 | Breast | Precancer | Salmonella infection | 49/684 | 249/8465 | 2.92e-09 | 6.15e-08 | 4.71e-08 | 49 |
hsa0513224 | Breast | IDC | Salmonella infection | 55/867 | 249/8465 | 2.07e-08 | 4.49e-07 | 3.36e-07 | 55 |
hsa0513234 | Breast | IDC | Salmonella infection | 55/867 | 249/8465 | 2.07e-08 | 4.49e-07 | 3.36e-07 | 55 |
hsa0513243 | Breast | DCIS | Salmonella infection | 55/846 | 249/8465 | 8.71e-09 | 1.87e-07 | 1.38e-07 | 55 |
hsa0513253 | Breast | DCIS | Salmonella infection | 55/846 | 249/8465 | 8.71e-09 | 1.87e-07 | 1.38e-07 | 55 |
hsa0513220 | Cervix | CC | Salmonella infection | 74/1267 | 249/8465 | 1.33e-09 | 2.54e-08 | 1.50e-08 | 74 |
hsa05132110 | Cervix | CC | Salmonella infection | 74/1267 | 249/8465 | 1.33e-09 | 2.54e-08 | 1.50e-08 | 74 |
hsa0513225 | Cervix | HSIL_HPV | Salmonella infection | 34/459 | 249/8465 | 5.03e-07 | 1.13e-05 | 9.17e-06 | 34 |
hsa0513235 | Cervix | HSIL_HPV | Salmonella infection | 34/459 | 249/8465 | 5.03e-07 | 1.13e-05 | 9.17e-06 | 34 |
hsa05132 | Colorectum | AD | Salmonella infection | 102/2092 | 249/8465 | 7.65e-09 | 1.28e-07 | 8.17e-08 | 102 |
hsa04962 | Colorectum | AD | Vasopressin-regulated water reabsorption | 19/2092 | 44/8465 | 5.48e-03 | 2.48e-02 | 1.58e-02 | 19 |
hsa051321 | Colorectum | AD | Salmonella infection | 102/2092 | 249/8465 | 7.65e-09 | 1.28e-07 | 8.17e-08 | 102 |
hsa049621 | Colorectum | AD | Vasopressin-regulated water reabsorption | 19/2092 | 44/8465 | 5.48e-03 | 2.48e-02 | 1.58e-02 | 19 |
hsa051322 | Colorectum | SER | Salmonella infection | 77/1580 | 249/8465 | 1.56e-06 | 2.35e-05 | 1.71e-05 | 77 |
hsa051323 | Colorectum | SER | Salmonella infection | 77/1580 | 249/8465 | 1.56e-06 | 2.35e-05 | 1.71e-05 | 77 |
hsa051324 | Colorectum | MSS | Salmonella infection | 92/1875 | 249/8465 | 5.23e-08 | 9.74e-07 | 5.97e-07 | 92 |
hsa049622 | Colorectum | MSS | Vasopressin-regulated water reabsorption | 17/1875 | 44/8465 | 9.76e-03 | 3.55e-02 | 2.18e-02 | 17 |
hsa051325 | Colorectum | MSS | Salmonella infection | 92/1875 | 249/8465 | 5.23e-08 | 9.74e-07 | 5.97e-07 | 92 |
hsa049623 | Colorectum | MSS | Vasopressin-regulated water reabsorption | 17/1875 | 44/8465 | 9.76e-03 | 3.55e-02 | 2.18e-02 | 17 |
Page: 1 2 3 4 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DYNLL1 | SNV | Missense_Mutation | rs11544060 | c.11N>A | p.Arg4Gln | p.R4Q | P63167 | protein_coding | tolerated(0.72) | benign(0.005) | TCGA-Q1-A5R2-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PR |
DYNLL1 | SNV | Missense_Mutation | novel | c.140N>T | p.Asp47Val | p.D47V | P63167 | protein_coding | deleterious(0) | possibly_damaging(0.834) | TCGA-ZJ-AAXI-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
DYNLL1 | SNV | Missense_Mutation | c.70T>C | p.Cys24Arg | p.C24R | P63167 | protein_coding | deleterious(0.05) | benign(0.03) | TCGA-A5-A0VP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
DYNLL1 | SNV | Missense_Mutation | novel | c.263C>A | p.Ser88Tyr | p.S88Y | P63167 | protein_coding | deleterious(0) | probably_damaging(0.968) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
DYNLL1 | deletion | Frame_Shift_Del | novel | c.220delA | p.Ile74SerfsTer36 | p.I74Sfs*36 | P63167 | protein_coding | TCGA-44-7672-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
DYNLL1 | deletion | Frame_Shift_Del | novel | c.222_225delCTAC | p.Tyr75SerfsTer34 | p.Y75Sfs*34 | P63167 | protein_coding | TCGA-44-7672-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
DYNLL1 | insertion | Frame_Shift_Ins | novel | c.176_177insT | p.Arg60GlufsTer5 | p.R60Efs*5 | P63167 | protein_coding | TCGA-85-8070-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | ||
DYNLL1 | SNV | Missense_Mutation | rs748141393 | c.100N>G | p.Ile34Val | p.I34V | P63167 | protein_coding | tolerated(0.57) | benign(0.007) | TCGA-CN-6988-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
DYNLL1 | SNV | Missense_Mutation | rs796315584 | c.65N>C | p.Val22Ala | p.V22A | P63167 | protein_coding | deleterious(0.05) | benign(0.13) | TCGA-VQ-A91D-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | fluorouracil | PD |
DYNLL1 | SNV | Missense_Mutation | novel | c.175N>T | p.Gly59Trp | p.G59W | P63167 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-E8-A2EA-01 | Thyroid | thyroid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |